179 related articles for article (PubMed ID: 35067084)
21. [Study on aberration in histone methylation and acetylation in acute leukemia].
Ma XD; Huang YQ; Xiao LY; Zou Y
Zhonghua Xue Ye Xue Za Zhi; 2010 Aug; 31(8):523-6. PubMed ID: 21122330
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic changes in the myelodysplastic syndrome.
Issa JP
Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
[TBL] [Abstract][Full Text] [Related]
23. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
24. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
25. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome.
Coffee B; Zhang F; Ceman S; Warren ST; Reines D
Am J Hum Genet; 2002 Oct; 71(4):923-32. PubMed ID: 12232854
[TBL] [Abstract][Full Text] [Related]
26. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
Soncini M; Santoro F; Gutierrez A; Frigè G; Romanenghi M; Botrugno OA; Pallavicini I; Pelicci P; Di Croce L; Minucci S
Biochim Biophys Acta; 2013 Jan; 1832(1):114-20. PubMed ID: 23046813
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide ChIP-seq mapping and analysis reveal butyrate-induced acetylation of H3K9 and H3K27 correlated with transcription activity in bovine cells.
Shin JH; Li RW; Gao Y; Baldwin R; Li CJ
Funct Integr Genomics; 2012 Mar; 12(1):119-30. PubMed ID: 22249597
[TBL] [Abstract][Full Text] [Related]
28. Genomic impact of transient low-dose decitabine treatment on primary AML cells.
Klco JM; Spencer DH; Lamprecht TL; Sarkaria SM; Wylie T; Magrini V; Hundal J; Walker J; Varghese N; Erdmann-Gilmore P; Lichti CF; Meyer MR; Townsend RR; Wilson RK; Mardis ER; Ley TJ
Blood; 2013 Feb; 121(9):1633-43. PubMed ID: 23297133
[TBL] [Abstract][Full Text] [Related]
29. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
30. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
31. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
32. Quantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass Spectrometry.
Krautkramer KA; Reiter L; Denu JM; Dowell JA
J Proteome Res; 2015 Aug; 14(8):3252-62. PubMed ID: 26120868
[TBL] [Abstract][Full Text] [Related]
33. Treatment of buffalo (Bubalus bubalis) donor cells with trichostatin A and 5-aza-2'-deoxycytidine alters their growth characteristics, gene expression and epigenetic status and improves the in vitro developmental competence, quality and epigenetic status of cloned embryos.
Saini M; Selokar NL; Agrawal H; Singla SK; Chauhan MS; Manik RS; Palta P
Reprod Fertil Dev; 2016 Apr; 28(6):824-37. PubMed ID: 25409339
[TBL] [Abstract][Full Text] [Related]
34. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
Hambach L; Ling KW; Pool J; Aghai Z; Blokland E; Tanke HJ; Bruijn JA; Halfwerk H; van Boven H; Wieles B; Goulmy E
Blood; 2009 Mar; 113(12):2715-22. PubMed ID: 19096014
[TBL] [Abstract][Full Text] [Related]
35. 5-azacytidine treatment reorganizes genomic histone modification patterns.
Komashko VM; Farnham PJ
Epigenetics; 2010 Apr; 5(3):229-40. PubMed ID: 20305384
[TBL] [Abstract][Full Text] [Related]
36. Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing.
Chen H; Ke Q; Kluz T; Yan Y; Costa M
Mol Cell Biol; 2006 May; 26(10):3728-37. PubMed ID: 16648469
[TBL] [Abstract][Full Text] [Related]
37. Quantitative proteomic analysis of post-translational modifications of human histones.
Beck HC; Nielsen EC; Matthiesen R; Jensen LH; Sehested M; Finn P; Grauslund M; Hansen AM; Jensen ON
Mol Cell Proteomics; 2006 Jul; 5(7):1314-25. PubMed ID: 16627869
[TBL] [Abstract][Full Text] [Related]
38. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Ikehata M; Ueda K; Iwakawa S
Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
[TBL] [Abstract][Full Text] [Related]
39. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications.
Zhang C; Li H; Wang Y; Liu W; Zhang Q; Zhang T; Zhang X; Han B; Zhou G
J Hepatol; 2010 Nov; 53(5):889-95. PubMed ID: 20675009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
